Pharming reacquires RUCONEST®-licensed territories from Sobi

''The transaction will enable us to drive further growth of RUCONEST® and will be accretive to earnings immediately. In addition, we will expand our existing commercial infrastructure in Europe to support the expected launch of future new products.'' — Sijmen de Vries - CEO Resources For further information, please contact: Media Relations Investor Relations Quick links

The release as fetched from its publisher. pharming.com ↗